UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000026321
Receipt number R000030232
Scientific Title A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study on Improvements in Glucose Metabolism by Daily Ingestion of Products Containing Pinitol
Date of disclosure of the study information 2017/02/27
Last modified on 2019/02/28 14:36:50

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study on Improvements in Glucose Metabolism by Daily Ingestion of Products Containing Pinitol

Acronym

Improvements in Glucose Metabolism by Daily Ingestion of Products Containing Pinitol

Scientific Title

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study on Improvements in Glucose Metabolism by Daily Ingestion of Products Containing Pinitol

Scientific Title:Acronym

Improvements in Glucose Metabolism by Daily Ingestion of Products Containing Pinitol

Region

Japan


Condition

Condition

Healthy adults

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the safety and usefulness of 12-weeks daily ingestion of products containing pinitol for improvements in glucose metabolism.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

HbA1c levels after 4, 8 and 12 weeks of ingestion and 4weeks after the end of ingestion.

Key secondary outcomes

Fasting blood glucose, glycoalbumin, insulin and HOMA-IR


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

YES

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

YES

Concealment

No need to know


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Ingestion of three capsules containing pinitol daily for 12 weeks.

Interventions/Control_2

Ingestion of three placebo capsules daily for 12 weeks.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

1. Subjects whose FBG is>=100mg/dl and <126mg/dl or HbA1c >=5.6% and <6.5%.
2. Subjects who have relatively high HOMA-IR levels (selected by the screening results).
3. Subjects who agree to participate in this study with a written informed consent.

Key exclusion criteria

1. Subjects who are under physician's advice, treatment and/or medication for diabetes.
2. Subjects whose HbA1c is >=6.5%
3. Subjects whose FBG is >=126 mg/dl.
4. Subjects with serious cerebrovascular, cardiac, hepatic, renal, gastrointestinal diseases, and/or affected with infectious diseases requiring reports to the authorities.
5. Subjects with major surgical history relevant to digestive system such as gastrectomy, gastrorrhaphy, enterectomy, etc.
6. Subjects with unusually high and/or low blood pressure and/or abnormal hematological data.
7. Subjects with severe anemia.
8. Pre- or post-menopausal women complaining obvious physical changes.
9. Subjects who are at risk of having allergic reactions to drugs or foods based on especially leguminous plants including soybeans, and ice plants, yeasts, gelatin and milk.
10. Subjects who regularly take medicine, functional foods and/or supplements (containing dietary fiber such as indigestible dextrin, polyphenol, etc.) which would affect glucose metabolism.
11. Heavy smokers, alcohol addicts or subjects with the eating disordered lifestyle.
12. Subjects who donated either 400ml whole blood within 16 weeks (women) /12 weeks (men) or 200ml whole blood within 4 weeks or blood components within 2 weeks prior to the current study.
13. Pregnant or lactating women or women expect to be pregnant during this study.
14. Subjects who currently participate in other clinical trials or participated within the last 4 weeks prior to the current study.
15. Any other medical and/ or health reasons unfavorable to participation into the current study judged by the principal investigator.

Target sample size

64


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Prof. Jun NISHIHIRA, M.D., Ph.D.

Organization

Hokkaido Information University

Division name

Department of Medical Management and Informatics

Zip code


Address

59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan

TEL

011-385-4411

Email

nishihira@do-johodai.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Dir. Prof. Jun NISHIHIRA, M.D., Ph.D.

Organization

Hokkaido Information University

Division name

Health Information Science Center

Zip code


Address

59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan

TEL

011-385-4430

Homepage URL


Email

nishihira@do-johodai.ac.jp


Sponsor or person

Institute

Hokkaido Information University

Institute

Department

Personal name



Funding Source

Organization

The Ethics Committee approves that the source of funding shall not be disclosed.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

北海道情報大学 保健センター(北海道)


Other administrative information

Date of disclosure of the study information

2017 Year 02 Month 27 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2016 Year 12 Month 21 Day

Date of IRB


Anticipated trial start date

2017 Year 02 Month 28 Day

Last follow-up date

2017 Year 07 Month 16 Day

Date of closure to data entry

2017 Year 08 Month 30 Day

Date trial data considered complete

2017 Year 09 Month 06 Day

Date analysis concluded

2017 Year 12 Month 20 Day


Other

Other related information



Management information

Registered date

2017 Year 02 Month 27 Day

Last modified on

2019 Year 02 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030232


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name